NCT05926882Phase 4Completed
Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi.
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Completed
- Declared phase
- Phase 4
- Sponsor
- Jinnah Postgraduate Medical Centre
- Participants (registry)
- 30
- Start
- August 2022
- Primary completion
- June 2023
- Study completion
- June 2023
- Last registry update
- July 2023
- Countries
- Pakistan
Conditions studied: Alopecia Areata
Interventions: Apremilast 30mg
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.